Building the future: global MedTech leader Ottobock completes IPO

Ottobock, the global market leader in Human Bionics, pursues its mission to empower people to maintain or regain their freedom of movement.

2 min

Ottobock SE & Co. KGaA has successfully completed its initial public offering (IPO). Total offer volume amounted to EUR 808 million (including Greenshoe), consisting of shares from the holding of the founding Näder family as well as newly issued shares from a capital increase. The company’s shares now trade on the Regulated Market (Prime Standard) of the Frankfurt Stock Exchange. BNP Paribas acted as Joint Global Coordinator and Joint Bookrunner.

Empowering customers for freedom of movement

Ottobock combines over 100 years of tradition with outstanding innovative strength in the fields of prosthetics, neuro-orthotics and exoskeletons for occupational use. Key product innovations include:

  • the C-Leg, the first real-time microprocessor-controlled knee prosthesis (MPK);
  • the C-Brace, a revolutionary lower-limb mechatronic neuro-orthotic device;
  • the Exopulse Suit, an innovative neuro-modulation device.

Ottobock’s business model is designed for global scale-up of high-tech innovations and long-term value creation. Today, Ottobock serves customers from more than 140 countries and over 650,000 patients annually. Its presence across the entire orthotics and prosthetics (O&P) value chain allows Ottobock to manage direct access to both technology and patients through its global network of around 400 patient-care clinics.

Oliver Jakobi, CEO of Ottobock: “The IPO marks an important milestone for Ottobock. For more than 100 years, the Company has stood for innovation and responsibility towards the people we serve. With the IPO, we are creating the foundation to carry this tradition into the future – with investments in cutting-edge technologies, sustainable growth, and the clear ambition to set new standards in Human Bionics.”

Innovating the future

“Congratulations to Ottobock for this transaction and for its future growth plans. We thank the founder family and the company’s management for their trust and for the opportunity to contribute our deep equity markets expertise to support a MedTech champion in its growth ambitions and to deliver for its clients,” said Christoph Heuer, Head of Investment Banking Germany at BNP Paribas CIB.

Supporting German Mittelstand family-owned businesses

Ottobock is one of the German Mittelstand companies, characterised by family ownership, a high degree of specialisation, as well as their focus on innovation and R&D. The company has also embedded responsible behaviour and sustainability within its operations. Its mission to restore and enhance human mobility for people of all abilities guides product development and shapes its commitments, community outreach programmes and responsible supply‑chain practices.

Find out more about BNP Paribas in Germany in an interview with Lutz Diederichs and Frank Vogel

HOT talks (with Lutz Diederichs and Frank Vogel)